Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec With or Without Metformin in Adults With Diabetes

Next Previous
X
Search
Trial Profile

Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec With or Without Metformin in Adults With Diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin degludec
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 06 Oct 2023 Primary endpoint (Change in glycosylated haemoglobin (HbA1c)) has not been met according to results presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
    • 06 Oct 2023 Results presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
    • 24 Aug 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top